View Item 

Show simple item record

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
dc.contributor.authorEimeren, Thilo
dc.contributor.authorAntonini, Angelo
dc.contributor.authorBerg, Daniela
dc.contributor.authorBohnen, Nico
dc.contributor.authorCeravolo, Roberto
dc.contributor.authorDrzezga, Alexander
dc.contributor.authorHöglinger, Günter U.
dc.contributor.authorHiguchi, Makoto
dc.contributor.authorLehericy, Stephane
dc.contributor.authorLewis, Simon
dc.contributor.authorMonchi, Oury
dc.contributor.authorNestor, Peter
dc.contributor.authorOndrus, Matej
dc.contributor.authorPavese, Nicola
dc.contributor.authorPeralta, María Cecilia
dc.contributor.authorPiccini, Paola
dc.contributor.authorPineda‐pardo, José Ángel
dc.contributor.authorRektorová, Irena
dc.contributor.authorRodríguez‐oroz, María
dc.contributor.authorRominger, Axel
dc.contributor.authorSeppi, Klaus
dc.contributor.authorStoessl, A. Jon
dc.contributor.authorTessitore, Alessandro
dc.contributor.authorThobois, Stephane
dc.contributor.authorKaasinen, Valtteri
dc.contributor.authorWenning, Gregor
dc.contributor.authorSiebner, Hartwig R.
dc.contributor.authorStrafella, Antonio P.
dc.contributor.authorRowe, James B.
dc.date.accessioned2020-01-13T15:03:59Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-01-13T15:03:59Z
dc.date.issued2019-12
dc.identifier.citationEimeren, Thilo; Antonini, Angelo; Berg, Daniela; Bohnen, Nico; Ceravolo, Roberto; Drzezga, Alexander; Höglinger, Günter U. ; Higuchi, Makoto; Lehericy, Stephane; Lewis, Simon; Monchi, Oury; Nestor, Peter; Ondrus, Matej; Pavese, Nicola; Peralta, María Cecilia ; Piccini, Paola; Pineda‐pardo, José Ángel ; Rektorová, Irena ; Rodríguez‐oroz, María ; Rominger, Axel; Seppi, Klaus; Stoessl, A. Jon; Tessitore, Alessandro; Thobois, Stephane; Kaasinen, Valtteri; Wenning, Gregor; Siebner, Hartwig R.; Strafella, Antonio P.; Rowe, James B. (2019). "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System." Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11(C): 301-309.
dc.identifier.issn2352-8729
dc.identifier.issn2352-8729
dc.identifier.urihttps://hdl.handle.net/2027.42/152532
dc.description.abstractIntroductionTherapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.MethodsTo promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.ResultsAs a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intentionâ toâ treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).DiscussionWe suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a wellâ defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.Highlightsâ ¢Challenges in ascribing utility of neuroimaging biomarkers in clinical trials.â ¢Criteria for utility of neuroimaging biomarkers in clinical trials.â ¢Proposition of a formalized and graded utility description system.
dc.publisherWiley Periodicals, Inc.
dc.publisherButterworths & Co.
dc.subject.otherCBS
dc.subject.otherBiomarker
dc.subject.otherTrials
dc.subject.otherPSP
dc.subject.otherMSA
dc.subject.otherCBD
dc.subject.otherNeurodegeneration
dc.subject.otherBiomarker
dc.subject.otherMulticentric
dc.subject.otherMultisite
dc.subject.otherNeuroimaging
dc.subject.otherHarmonization
dc.subject.otherPET
dc.subject.otherMRI
dc.titleNeuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152532/1/dad2jdadm201901011.pdf
dc.identifier.doi10.1016/j.dadm.2019.01.011
dc.identifier.sourceAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
dc.identifier.citedreferenceG.K. Wenning, F. Geser, F. Krismer, K. Seppi, S. Duerr, S. Boesch, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 12: 2013; 264 â 274
dc.identifier.citedreferenceT.E. Cope, T. Rittman, R.J. Borchert, P.S. Jones, D. Vatansever, K. Allinson, et al. Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy. Brain. 141: 2018; 550 â 567
dc.identifier.citedreferenceJ.J. Palop, J. Chin, L. Mucke. A network dysfunction perspective on neurodegenerative diseases. Nature. 443: 2006; 768
dc.identifier.citedreferenceD.R. Williams, A.J. Lees. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 8: 2009; 270 â 279
dc.identifier.citedreferenceS. Gilman, G. Wenning, P.A. Low, D. Brooks, C. Mathias, J. Trojanowski, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 71: 2008; 670 â 676
dc.identifier.citedreferenceG.G. Kovacs. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 41: 2015; 3 â 23
dc.identifier.citedreferenceM.D. Cykowski, E.A. Coon, S.Z. Powell, S.M. Jenkins, E.E. Benarroch, P.A. Low, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 138: 2015; 2293 â 2309
dc.identifier.citedreferenceH. Braak, K. Del Tredici, U. Rüb, R.A. de Vos, E.N. Jansen Steur, E. Braak. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 24: 2003; 197 â 211
dc.identifier.citedreferenceS.S. O’Sullivan, L.A. Massey, D.R. Williams, L. Silveiraâ Moriyama, P.A. Kempster, J.L. Holton, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 131: 2008; 1362 â 1372
dc.identifier.citedreferenceR. Constantinescu, I. Richard, R. Kurlan. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord. 22: 2007; 2141 â 2148
dc.identifier.citedreferenceM.C. Hoenig, G.N. Bischof, J. Seemiller, J. Hammes, J. Kukolja, Ã .A. Onur, et al. Networks of tau distribution in Alzheimer’s disease. Brain. 141: 2018; 568 â 581
dc.identifier.citedreferenceI. Litvan. What is an Atypical Parkinsonian Disorder?. In: I. Litvan. Atypical parkinsonian disorders: clinical and research aspects. 2005; Humana Press: Totowa, NJ; 1 â 10
dc.identifier.citedreferenceK. Jellinger. The pathology of parkinsonism. In: C.D. Marsden, S. Fahn. Mov Disord. 1987; Butterworths & Co.: London; 124 â 165
dc.identifier.citedreferenceA. Elbaz, L. Carcaillon, S. Kab, F. Moisan. Epidemiology of Parkinson’s disease. Rev Neurol (paris). 172: 2016; 14 â 26
dc.identifier.citedreferenceJ. Horvath, P.R. Burkhard, C. Bouras, E. Kövari. Etiologies of Parkinsonism in a Century Long Autopsy Based Cohort. Brain Pathol. 23: 2013; 28 â 33
dc.identifier.citedreferenceM.C. Hoenig, G.N. Bischof, J. Hammes, J. Faber, K. Fliessbach, T. van Eimeren, et al. Tau pathology and cognitive reserve in Alzheimer’s disease. Neurobiol Aging. 57: 2017; 1 â 7
dc.identifier.citedreferenceY. Stern. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 8: 2002; 448 â 460
dc.identifier.citedreferenceE.J. Gallagher. The problem with sensitivity and specificityâ ¦. Ann Emerg Med. 42: 2003; 298 â 303
dc.identifier.citedreferenceFDAâ NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. 2016; Food and Drug Administration (US): Silver Spring (MD), Available from http://www.ncbi.nlm.nih.gov/books/NBK326791/
dc.identifier.citedreferenceJ. Joutsa, M. Gardberg, M. Röyttä, V. Kaasinen. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 20: 2014; 840 â 844
dc.identifier.citedreferenceG. Rizzo, M. Copetti, S. Arcuti, D. Martino, A. Fontana, G. Logroscino. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and metaâ analysis. Neurology. 86: 2016; 566 â 576
dc.identifier.citedreferenceS.E. Lee, G.D. Rabinovici, M.C. Mayo, S.M. Wilson, W.W. Seeley, S.J. DeArmond, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 70: 2011; 327 â 340
dc.identifier.citedreferenceG.U. Höglinger, G. Respondek, M. Stamelou, C. Kurz, K.A. Josephs, A.E. Lang, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 32: 2017; 853 â 864
dc.identifier.citedreferenceA. Castro Caldas, J. Levin, R. Djaldetti, O. Rascol, G. Wenning, J.J. Ferreira, et al. Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. Mov Disord. 32: 2017; 1356 â 1364
dc.identifier.citedreferenceA.L. Boxer, J.â T. Yu, L.I. Golbe, I. Litvan, A.E. Lang, G.U. Höglinger. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 16: 2017; 552 â 563
dc.identifier.citedreferenceA.P. Strafella, N.I. Bohnen, N. Pavese, D.E. Vaillancourt, T. van Eimeren, M. Politis, et al. Imaging markers of progression in Parkinson’s disease. Mov Disord Clin Pract. 5: 2018; 586 â 596
dc.identifier.citedreferenceT. van Eimeren, G.N. Bischof, A. Drzezga. Is Tau Imaging More Than Just Upsideâ Down 18Fâ FDG Imaging?. J Nucl Med. 58: 2017; 1357 â 1359
dc.identifier.citedreferenceA.P. Strafella, N.I. Bohnen, J.S. Perlmutter, D. Eidelberg, N. Pavese, T. Van Eimeren, et al. Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord. 32: 2017; 181 â 192
dc.identifier.citedreferenceJ.L. Whitwell, G.U. Höglinger, A. Antonini, Y. Bordelon, A.L. Boxer, C. Colosimo, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?. Mov Disord. 32: 2017; 955 â 971
dc.identifier.citedreferenceC. Jack, M. Shiung, J. Gunter, P. O’brien, S. Weigand, D. Knopman, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 62: 2004; 591 â 600
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dad2jdadm201901011.pdf
Size:
811.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.